INTRODUCTION AND OBJECTIVE
Bremelanotide is FDA approved for premenopausal women with generalized, acquired hypoactive sexual desire disorder (HSDD). It modulates dopaminergic pathways involved in sexual desire and arousal in men and women and has been reported to increase genital blood flow...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.